Journal of Nuclear Medicine
The Journal of Nuclear Medicine (JNM)—self-published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a nonprofit, international scientific and professional organization—offers readers around the globe clinical investigations, basic science reports, continuing education articles, book reviews, employment opportunities, and updates on rapidly …
Table of Contents — January 01, 2025, 66 (1) | Journal of Nuclear …
Jan 1, 2025 · PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177 Lu-PSMA-617: Importance of 18 F-FDG–Avid Discordant Findings
JNM Information for Authors | Journal of Nuclear Medicine
Editorial Policy. The Journal of Nuclear Medicine (JNM) publishes material of interest to practitioners and scientists in the fields of nuclear medicine and molecular imaging.Proffered articles describing original laboratory or clinical investigations, brief communications, and letters to the editor will be considered for publication.
Published Ahead of Print - The Journal of Nuclear Medicine
The Journal of Nuclear Medicine (JNM)—self-published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a nonprofit, international scientific and professional organization—offers readers around the globe clinical investigations, basic science reports, continuing education articles, book reviews, employment opportunities, and updates on rapidly …
About Us | Journal of Nuclear Medicine
The Journal of Nuclear Medicine (JNM)—self-published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a nonprofit, international scientific and professional organization—offers readers around the globe clinical and basic science investigations, continuing education articles, state-of-the-art reviews, employment opportunities, and updates on rapidly …
Rates of PSMA PET Staging and Positivity in Newly Diagnosed …
Jan 1, 2025 · Prostate-specific membrane antigen (PSMA) PET was approved by the U.S. Food and Drug Administration in 2020 for the staging of newly diagnosed prostate cancer, yet rates of adoption and real-world positivity rates are unknown. We characterized patients undergoing PSMA PET staging and describe positive findings in a large national cohort.
Archive of all online content | Journal of Nuclear Medicine
Jan 1, 2025 · Explore the archive of all online content from the Journal of Nuclear Medicine, including clinical investigations, basic science reports, and continuing education articles.
June 01, 2023, 64 (supplement 1) - Journal of Nuclear Medicine
Aug 28, 2023 · Toward Single-Time-Point Image-Based Dosimetry of 177 Lu-PSMA-617 Therapy
Table of Contents — November 01, 2024, 65 (11) | Journal of …
Nov 1, 2024 · Efficacy and Toxicity of [177 Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data
Table of Contents — May 01, 2023, 64 (5) - Journal of Nuclear …
64 Cu Treatment Planning and 67 Cu Therapy with Radiolabeled [64 Cu/ 67 Cu]MeCOSar-Octreotate in Subjects with Unresectable Multifocal Meningioma: Initial Results for Human Imaging, Safety, Biodistribution, and Radiation Dosimetry